These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32081671)

  • 1. Fate of Pediatric Renal Angiomyolipoma During mTOR Inhibitor Treatment in Tuberous Sclerosis Complex.
    Wu CQ; Wolf DS; Smith EA
    Urology; 2020 May; 139():161-167. PubMed ID: 32081671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study.
    Su R; Huang T; Gu L; Bao Y; Liu Z; Dao P; Yao L; Hu X; Fu G; Wu J; Tricard T; Wu G; Chen M; Li C; Huang Z; Zheng B; Chen Y; Xue W; Guo G; Dong P; Huang J; Zhang J
    Cancer Med; 2024 Sep; 13(17):e70181. PubMed ID: 39279295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
    Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density.
    Hatano T; Atsuta M; Inaba H; Endo K; Egawa S
    Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy.
    Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G
    Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HUGE RENAL ANGIOMYOLIPOMA (AML) IN TUBEROUS SCLEROSIS COMPLEX (TSC) WHICH IS CONTROLED BY EVEROLIMUS: A CASE REPORT].
    Kanbara T; Sakaeda K; Kusaka N; Akebi N
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):54-58. PubMed ID: 28132993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous low-dose everolimus shrinkage tuberous sclerosis complex-associated renal angiomyolipoma: a 48-month follow-up study.
    Wei CC; Tsai JD; Sheu JN; Chen SL; Tsao TF; Yang SH; Tsai JD
    J Investig Med; 2019 Mar; 67(3):686-690. PubMed ID: 30455224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
    Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.
    Hatano T; Inaba H; Endo K; Egawa S
    Int J Urol; 2017 Nov; 24(11):780-785. PubMed ID: 28905429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
    Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex.
    Hatano T; Endo K; Tamari M
    Int J Clin Oncol; 2021 Jan; 26(1):163-168. PubMed ID: 32990779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.
    Kingswood JC; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D' Amato L; d'Augères GB; de Vries PJ; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC
    Nephrol Dial Transplant; 2019 Mar; 34(3):502-508. PubMed ID: 29697822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN
    Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
    PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.
    Samueli S; Abraham K; Dressler A; Gröppel G; Mühlebner-Fahrngruber A; Scholl T; Kasprian G; Laccone F; Feucht M
    Orphanet J Rare Dis; 2016 Nov; 11(1):145. PubMed ID: 27809914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
    Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
    Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
    Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
    J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.